WuXi Biologics reports share option exercises, buyback cancellation

WuXi Biologics (Cayman) Inc. reported an initial balance of 4,087,867,673 issued shares as of September 30, 2025. The company experienced several changes in its issued share capital through October 16, 2025, primarily due to the exercise of share options under its Pre-IPO Share Option Scheme. These exercises occurred on various dates, with new shares issued at prices ranging from HK$1.29 to HK$2.64. Notable issuances included 4,043 shares on October 2, 2025, 5,400 shares on October 6, 2025, and 95,000 shares on October 13, 2025.

The most significant event was the cancellation of 23,180,000 repurchased shares on October 16, 2025, which were originally repurchased on July 8 and July 9, 2025. This cancellation reduced the overall number of issued shares, with the repurchased shares having an average price of HK$25.75 per share.

Following these transactions, the closing balance of issued shares as of October 16, 2025, stands at 4,064,897,754. All transactions were confirmed to be duly authorized and in compliance with listing rules. The company confirmed that all securities issued are identical in all respects.